Intensified polarization in R&D investment among listed pharms

Although it is estimated there were more than 6 listed pharmaceutical companies investing more than KRW 100 billion into R&D in a year, there were also a number of pharmaceutical products spending less than 1% of their sales into R&D, which raised a criticism about polarization of R&D in the pharmaceutical industry.

According to the Yakup Shinmoon’s(www.yakup.com) analysis result of 2017 1^st q...